Intended for healthcare professionals


NICE allows immunotherapy treatment for small group of patients with advanced triple negative breast cancer

BMJ 2022; 377 doi: (Published 24 May 2022) Cite this as: BMJ 2022;377:o1311
  1. Jacqui Wise
  1. Kent

The National Institute for Health and Care Excellence (NICE) has now ruled that pembrolizumab (Keytruda) plus chemotherapy should be available as a treatment option for a limited group of patients with advanced triple negative breast cancer.1

In March 2022 NICE published draft guidance that said the immunotherapy treatment was not a cost effective use of resources.2

Pembrolizumab, which is given by injection every three weeks, is a type of immunotherapy that works by blocking the protein PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person’s own immune cells to attack …

View Full Text

Log in

Log in through your institution


* For online subscription